EGFR and non-small cell lung carcinoma: An ongoing phase 3 trial of dacomitinib in advanced NSCLC unresponsive to standard therapy, including one to three lines of chemotherapy and an EGFR TKI (BR26; NCT01000025), is not focused on molecularly selected patients; however, its secondary endpoints include OS in EGFR mutation-positive or wild-type KRAS subsets.